© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of May 22, 2015, the consensus forecast amongst 24 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 20 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 124.00, with a high estimate of 159.00 and a low estimate of 84.00. The median estimate represents a 11.00% increase from the last price of 111.71. View Full Financials
Historical dividend information is not available for Gilead Sciences Inc. View Full Financials
|Div growth (TTM)||--|
On Apr 30, 2015, Gilead Sciences, Inc. reported 1st quarter 2015 earnings of 2.94 per share. This result exceeded the 2.32 consensus of the 21 analysts covering the company and exceeded last year's 1st quarter results by 98.65%.
The next earnings announcement is expected on Jul 21, 2015. View Full Interim Financials
|Average growth rate||+21.46 %|
Gilead Sciences, Inc. reported annual 2014 earnings of 8.09 per share on Feb 03, 2015. View Full Annual Financials
|Average growth rate||+76.71 %|
Gilead Sciences Inc. had 1st quarter 2015 revenues of 7.59bn. This bettered the 6.89bn consensus of the 18 analysts covering the company. This was 3.83% above the prior year's 1st quarter results. View Full Interim Financials
|Average growth rate||+12.02 %|
Gilead Sciences Inc. had revenues for the full year 2014 of 24.89bn. This was 122.20% above the prior year's results. View Full Annual Financials
|Average growth rate||+39.71 %|